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REVIEW OF SOLUBLE BIOMARKERS OF OSTEOARTHRITIS: LESSONS
FROM ANIMAL MODEL
C. Legrand, C. Lambert, F. Comblain, C. Sanchez, Y. Henrotin. Univ. of
Liege, Liege, Belgium
Purpose: Osteoarthritis (OA) is one of the leading causes of disability
within the adult population. Currently, its diagnosis is mainly based on
clinical examination and standard radiography. To date, there is no way
to detect the disease at a molecular level, before the appearance of
structural changes and symptoms. So an attractive alternative for
monitoring OA is the measurement of biochemical markers in blood,
urine or synovial ﬂuid, which could reﬂect metabolic changes in joint
tissue and therefore disease onset and progression. Animal models are
relevant to investigate the early stage of OA and metabolic changes
occurring in joint tissues. The goal of this review is to summarize the
scientiﬁc data available in the literature on soluble biomarkers in ani-
mal models of OA.
Methods: A literature search was conducted using the Pubmed/Med-
line and Scopus databases between February 1995 and December 2014.
All original papers, systematic and narrative reviews published in
French or in English were considered.
Results: We summarized the data of 59 studies and proposed a clas-
siﬁcation scheme for OA biomarkers in animal studies, largely inspired
of the BIPED classiﬁcation. The most investigated biomarkers in terms
of burden of disease assessment are those derived from type II collagen
metabolism. Most particularly, Coll2-1 is particularly precocious. In
serum of guinea pig, Coll2-1 increase is coincident with the early dis-
ruption of the collagen ﬁbril visible by birefringence before the
appearance of structural changes observable by conventional micro-
scopy. Many interventions have been tested in rat, dog, horse and
guinea pig models using biomarkers derived from type II collagen and
aggrecan. Among diagnostic biomarkers, in guinea-pigs, only the ratioC2C/CPII were demonstrated to discriminate OA-prone Hartley and
strain 13 animals. Moreover, in mice, serum levels of MDA, CTX-II and
CPII were elevated in obese and hyperlipidemic STR/ORT (STR) mice
compared to control CBA mice. Finally, to our knowledge there is no
biomarker that can be classiﬁed as prognostic biomarkers.
Conclusions: In conclusion, this systematic review indicates that some
markers could be valuable to evaluate the burden of OA disease and to
assess the therapeutic response in animal models. The most inves-
tigated biomarker in terms of burden of disease assessment are those
derived from type II collagenmetabolism. Since OA represents a process
of matrix damage, turnover, and attempted repair, the use of multiple
biomarkers, both anabolic and catabolic, could likely be most accurate
in characterizing OA disease. Finally, soluble biomarkers can be as useful
“drug development tools” that should be early integrated in the
research program of new drugs.
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ANALYSIS OF THE EXPRESSION OF CONNEXIN 43 IN SYNOVIAL
TISSUE OF PATIENTS WITH ARTHRITIS
S. Shimomura y, S. Tsuchida y, Y. Arai y, S. Nakagawa y, H. Inoue y,
S. Ichimaru y, O. Mazda z, T. Kubo y. yDept. of Orthopedics, Graduate Sch.
of Med. Sci., Kyoto Prefectural Univ. of Med., Kyoto, Japan; zDept. of
Immunology, Graduate Sch. of Med. Sci., Kyoto Prefectural Univ. of Med.,
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Purpose: Connexins, the major proteins of gap junctions, are expressed
in various cell types and are important in the key process of intercellular
communication. Connexins 26, 32 and 43 are expressed in synovio-
cytes, and connexin 43 (Cx43) is the most highly expressed connexin in
normal human synovial membranes. Cx43 regulates immunological
response in several tissues such as kidneys and lungs. Although, the role
of Cx43 in synovium of arthritis is almost unclear. The aim of this study
is to examine the expression level of Cx43 gene in synovial tissue in
patients with rheumatoid arthritis (RA) compared with osteoarthritis.
Methods: The expression of Cx43 in synovial tissue from eight patients
with RA (2 males, 6 females; mean age 59.5± 2.7 years; range 52 to 71
years), ﬁve patients with osteoarthritis (2 males, 3 females; mean age
68.4± 2.7 years; range 61 to 81 years), and one normal female subject
(mean age 61 year) was analyzed by quantitative reverse transcriptase
polymerase chain reaction (RT-PCR) and immunohistochemistry of
tissue sections. All patients was analyzed with their demographic and
clinical features about disease duration, Larsen scores for RA, CRP levels
on presurgery, the disease activity scores including a 28-joint count
(DAS 28ESR), and their medication.
Results: Cx 43 was highly expressed in RA synovial tissue, which TNF-a
was also highly expressed, but was expressed lower in osteoarthritis
and normal synovial tissue than in RA. The expression of Cx43 protein
was highly in the superﬁcial and sublining layers of RA synovium. But
one of all patients with RA was not highly expressed. The expression of
Cx43 and TNF-a mRNAwere hardly detected in OA and normal synovial
tissue. All of the RA patients were being treated with disease-modifying
anti-rheumatic drugs (methotrexate or bucillamine or sulfasalazine),
four patients were also receiving corticosteroids and two patients were
also receiving an anti-IL-6 monoclonal antibody therapy (tocilizumab).
Disease duration of RA patients were ranged 7 to 29 years(mean
duration 15.4 years). All of their Larsen score for RA are stage IV. Their
CRP levels on presurgery are ranged 0.03 to 2.31(mean level 0.70). Their
DAS 28ESR patients were similar score (mean score 3.81± 1.22 range
3.64 to 5.03).
Conclusions: This study showed that Cx43 was strongly expressed in
RA patients and TNF-a expression was also highly expressed. In our
previous study, we demonstrated that siRNA targeting rat Cx43
inhibited TNF-a, IL-6, and IL-1b induced by lipopolysaccharide in rat
ﬁbroblast-like synoviocytes, and that transfection of siRNA targeting rat
Cx43 in the joint signiﬁcantly reduced synovitis in CIA rats. These
observations suggest that the high expression level of Cx43 may be
accompanied by TNF-a expression in synovial tissue of RA patient. On
the other hand, Cx43 was not highly expressed in synovium of one of all
RA patients. In this RA patient, the demographic and clinical features,
such as disease duration, Larsen scores for RA, CRP levels, DAS 28ESR,
and their medication, were not so different from other RA patients. This
suggest that the expression of Cx43 may be involved in a mechanism of
synovitis which is unregulated by the existing factors of disease activity
of RA, such as pro-inﬂammatory cytokines. Thus, Cx43 might be a novel
marker of inﬂammation in RA synovial tissue.
